124 related articles for article (PubMed ID: 1397031)
1. Preferential small arteriolar vasodilatation by the potassium channel opener, BRL 38227, in conscious spontaneously hypertensive rats.
Struijker Boudier HA; Messing MW; van Essen H
Eur J Pharmacol; 1992 Jul; 218(1):191-3. PubMed ID: 1397031
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
Lawson K; Barras M; Zazzi-Sudriez E; Martin DJ; Armstrong JM; Hicks PE
Br J Pharmacol; 1992 Sep; 107(1):58-65. PubMed ID: 1422579
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
[TBL] [Abstract][Full Text] [Related]
4. Increased vasodilator responsiveness to BRL 34915 in spontaneously hypertensive versus normotensive rats: contrast with nifedipine.
Falotico R; Keiser J; Haertlein B; Cheung WM; Tobia A
Proc Soc Exp Biol Med; 1989 Feb; 190(2):179-85. PubMed ID: 2915996
[TBL] [Abstract][Full Text] [Related]
5. Effects of cromakalim, a potassium channel opener, on regional blood flow in conscious spontaneously hypertensive rats.
Shoji T; Aki Y; Fukui K; Tamaki T; Iwao H; Abe Y
Eur J Pharmacol; 1990 Sep; 186(1):119-23. PubMed ID: 2282933
[TBL] [Abstract][Full Text] [Related]
6. The individual enantiomers of cis-cromakalim possess K+ channel opening activity.
Quast U; Villhauer EB
Eur J Pharmacol; 1993 Apr; 245(2):165-71. PubMed ID: 8491256
[TBL] [Abstract][Full Text] [Related]
7. Microvascular actions of calcium channel antagonists.
Messing M; Van Essen H; Smith TL; Smits JF; Struyker-Boudier HA
Eur J Pharmacol; 1991 Jun; 198(2-3):189-95. PubMed ID: 1650702
[TBL] [Abstract][Full Text] [Related]
8. Effects of NG-nitro-L-arginine methyl ester on vasodilator responses to adrenaline or BRL 38227 in conscious rats.
Gardiner SM; Kemp PA; Bennett T
Br J Pharmacol; 1991 Nov; 104(3):731-7. PubMed ID: 1797333
[TBL] [Abstract][Full Text] [Related]
9. The antihypertensive property of NIP-121, a novel potassium channel opener in rats.
Masuda Y; Arakawa C; Yokoyama T; Shigenobu K; Tanaka S
J Cardiovasc Pharmacol; 1991 Aug; 18(2):190-7. PubMed ID: 1717778
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced endothelium-dependent and -independent relaxations in isolated resistance vessels taken from simultaneously hypertensive and streptozotocin-diabetic rats.
Kam KL; Pfaffendorf M; van Zwieten PA
Blood Press; 1994 Nov; 3(6):418-27. PubMed ID: 7704291
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the vasodilatation by the K+ channel openers: cromakalim and pinacidil.
Rhim BY; Lee WS; Hong KW
Jpn J Pharmacol; 1992; 58 Suppl 2():335P. PubMed ID: 1507584
[No Abstract] [Full Text] [Related]
12. Studies on the anti-vasoconstrictor activity of BRL 34915 in spontaneously hypertensive rats; a comparison with nifedipine.
Buckingham RE
Br J Pharmacol; 1988 Mar; 93(3):541-52. PubMed ID: 3370388
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats.
Shin HS; Seo HW; Oh JH; Lee BH
Arzneimittelforschung; 1998 Oct; 48(10):969-78. PubMed ID: 9825113
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of Ro 31-6930, a new potassium channel opener.
Paciorek PM; Burden DT; Burke YM; Cowlrick IS; Perkins RS; Taylor JC; Waterfall JF
J Cardiovasc Pharmacol; 1990 Feb; 15(2):188-97. PubMed ID: 1689412
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of the novel potassium channel opener UR-8225.
Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
[TBL] [Abstract][Full Text] [Related]
16. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
17. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
Cavero I; Mondot S; Mestre M
J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353
[TBL] [Abstract][Full Text] [Related]
18. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
Cavero I; Pratz J; Mondot S
Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
[TBL] [Abstract][Full Text] [Related]
19. The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K(+) channel opener.
Lee YM; Yen MH; Peng YY; Sheu JR; Chen YC; Chang MJ; Cheng CY
Eur J Pharmacol; 2000 May; 397(1):151-60. PubMed ID: 10844109
[TBL] [Abstract][Full Text] [Related]
20. Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
Nakajima T; Shinohara T; Yaoka O; Fukunari A; Shinagawa K; Aoki K; Katoh A; Yamanaka T; Setoguchi M; Tahara T
J Pharmacol Exp Ther; 1992 May; 261(2):730-6. PubMed ID: 1578381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
